Skip to main content

Table 1 Baseline characteristics % (n) for the two study groups HFpEF (> 50%) and HFrEF (< 40%) n = 4761

From: Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure

VariablesHFpEF > 50%
% (n = 930)
HFrEF < 40%
% (n = 3831)
p-value
Demographic characteristics
 Female sex49 (456)27 (1047)< 0.001
 Age (over 75 years old)60 (555)36 (1363)< 0.001
 Smoker (n = 4290)10 (80)13 (469)0.007
a Cardiology clinic (n = 4419)61 (452)59 (2170)0.362
a Follow up referral to hospital (n = 4673)61 (560)87 (3275)< 0.001
 Follow up referral to out-patient heart failure nurse (n = 4657)55 (503)76 (2839)< 0.001
Medical history
 NYHA classification grades III / IV (n = 4476)33 (274)38 (1374)0.014
 Fatigue - pronounced/severe limitations (n = 4726)34 (314)29 (1098)0.002
 Shortness of breath - pronounced/severe limitations (n = 4731)35 (319)31 (1167)0.020
 Duration of heart failure ≥6 months (n = 4723)46 (427)36 (1360)< 0.001
 Ischaemic heart disease (n = 4474)36 (323)44 (1580)< 0.001
 Previous myocardial infarction (n = 2850)26 (126)35 (820)< 0.001
 Hypertension (n = 4635)61 (561)44 (1646)< 0.001
 Atrial fibrillation/flutter (n = 4738)55 (509)43 (1624)< 0.001
 Diabetes (n = 4741)25 (229)20 (767)0.002
 Pulmonary disease (n = 4693)19 (174)14 (515)< 0.001
 Anaemia (n = 4760)33 (306)23 (881)< 0.001
aCoexisting condition
  1 disease14 (128)21 (822)< 0.001
  2 diseases25 (229)24 (915) 
  3 diseases26 (245)21 (795) 
  4 diseases31 (291)24 (902) 
 Mean heart rate ≥ 70 bpm (n = 4701)53 (482)55 (2085)0.166
Laboratory examinations
 Reduced renal function (e-GFR < 60 μmol/L)46 (431)36 (1376)< 0.001
Drugs being taken
 ACEI/ARB82 (761)96 (3684)< 0.001
 β-blocker (n = 4750)82 (757)93 (3559)< 0.001
 MRA (n = 4738)21 (199)31 (1185)< 0.001
 Diuretic (n = 4738)77 (712)75 (2848)0.169
  1. a NOTE: Cardiology clinic; Cardiology vs. Medicine/Geriatrics. Follow up referral to hospital; Hospital vs. Primary care; Coexisting conditions; Ischaemic heart disease, Previous myocardial infarction, Hypertension, Atrial fibrillation/flutter, Pulmonary disease, Diabetes, Anaemia
  2. Abbreviations: ACEI Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin II Receptor Blocker, e-GFR estimated Glomerular Filtration Rate, HFrEF Heart failure with reduced ejection fraction, HFpEF Heart failure with preserved ejection fraction, MRA Mineralocorticoid Receptor Antagonist, NYHA New York Heart Association